 - 1. All patients must be female. 2. Signed informed consent. 3. Locally advanced breast cancers or primary breast cancers with concomitant metastatic disease are eligible. Locally advanced cancers must be of clinical andor radiologic size 4 cm andor are deemed surgically inoperable. 4. Negative serum pregnancy test within 7 days of starting study, if of child-bearing potential. 5. Adequate bone marrow function: Hematocrit of greater than 30, total neutrophil count must be 1.5 x 109L and platelets of 100 x 109L prior to the start of any cycle. 6. Kidney function tests - within 1.5 times of the institutions upper limit of normal. Total serum bilirubin within upper limit of normal. 7. Electrocardiogram showing no acute ischemic changes. 8. Performance status WHO scale 2 Appendix I and life expectancy 1 year. 9. Age 18 years. 10. No brain andor leptomeningeal disease. 11. No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. 